Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 5/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20759436 | 0.84 | MKNK2 (0.46) | HTR2AHTR2CHTR2BPARP1PIM1 | |
| SCHEMBL21633640 | 0.79 | PARP10 (0.40) | PARP10PARP11GRM5CYP1A2OGA | |
| SCHEMBL20779670 | 0.76 | GRM5 (0.38) | PARP10PARP11GRM5CYP1A2OGA | |
| SCHEMBL951278 | 0.76 | CDC7 (0.50) | — | |
| SCHEMBL3042595 | 0.75 | CSNK1A1 (0.43) | MAP4K1GRM5CYP1A2OGAHTR2A | |
| SCHEMBL15880368 | 0.75 | CCNA2 (0.39) | PARP10PARP11GRM5CYP1A2OGA | |
| SCHEMBL2471711 | 0.75 | GRM5 (0.38) | PARP10PARP11GRM5CYP1A2OGA | |
| SCHEMBL10220388 | 0.74 | SMN1; SMN2 (0.49) | GRM5 | |
| SCHEMBL26453573 | 0.73 | PARP10 (0.45) | MAP4K1PARP10PARP11GRM5CYP1A2 | |
| SCHEMBL23119368 | 0.73 | OGA (0.38) | MAP4K1PARP10PARP11GRM5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | ASCENEURON SA (CH) | 2021-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | GAA, ENGASE, BACE1 | MAP4K1 4783/4885PARP10 1214/4885PARP11 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.